Sort
82,697 grants matching “vaccine development”
DIVINCI: Dissection of Influenza Vaccination and Infection for Childhood Immunity
$5,000,729Paul Glyndwr Thomas · St. Jude Children'S Research Hospital · U01 · FY2019 · AI
IID Vaccine Evaluation and Development
$5,000,000David Heimbrook · Leidos Biomedical Research, Inc. · N01 · FY2014 · CA
HIV Active and Passive Clinical Material Manufacturing
$5,000,000David Heimbrook · Leidos Biomedical Research, Inc. · N01 · FY2014 · CA
NSF Convergence Accelerator Track F: Course Correct: Precision Guidance Against Misinformation
$5,000,000Michael W Wagner · University Of Wisconsin-Madison · · FY2022 · TIP
VACCINE TECHNOLOGIES TO ADVANCE NEXT GENERATION ANTHRAX VACCINES
$4,999,700Howard Tranter · · N01 · FY2019 · AI
Harvard University Center for AIDS Research
$4,998,801Rajesh T Gandhi · Harvard University · P30 · FY2021 · AI
Delaney AIDS Research Enterprise to Cure HIV
$4,998,394Steven Grant Deeks · University Of California, San Francisco · UM1 · FY2025 · AI
Immunologic and Virologic Basis of RhCMV/SIV Vaccine-Induced Replication Arrest Efficacy
$4,983,192Louis J. Picker · Oregon Health & Science University · P01 · FY2022 · AI
Immunoprophylactic Strategies to Control Emerging Enteric Infections
$4,973,548Myron Max Levine · University Of Maryland Baltimore · U19 · FY2018 · AI
DIVINCI: Dissection of Influenza Vaccination and Infection for Childhood Immunity
$4,966,751Paul Glyndwr Thomas · St. Jude Children'S Research Hospital · U01 · FY2020 · AI
Biodefense and Emerging Infectious Disease Vaccine Studies
$4,962,764Julie E. Ledgerwood · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
HIV Monoclonal Antibody Studies
$4,954,063Lesia Dropulic · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI
Immunoprophylactic Strategies to Control Emerging Enteric Infections
$4,950,326Myron Max Levine · University Of Maryland Baltimore · U19 · FY2015 · AI
TAS::75 0885::TASEXTERNAL QUALITY ASSURANCE PROGRAM OVERSIGHT LABORATORY
$4,942,168Thomas N Denny · Duke University · N01 · FY2010 · AI
Innovative Platforms for Antimicrobial Therapy and Vaccine Development
$4,937,887Dennis L. Kasper · Harvard Medical School · U19 · FY2014 · AI
Innovative Platforms for Antimicrobial Therapy and Vaccine Development
$4,932,536Dennis L. Kasper · Harvard Medical School · U19 · FY2015 · AI
Development/production of universal influenza vaccines
$4,931,770Jason Gall · National Institute Of Allergy And Infectious Diseases · ZIB · FY2025 · AI
Harvard University Center for AIDS Research
$4,926,244Rajesh T Gandhi · Harvard University · P30 · FY2022 · AI
Allogeneic and Autologous Immunotherapy for cancer and nonmalignant hematological disorders
$4,926,222Richard Childs · National Heart, Lung, And Blood Institute · ZIA · FY2024 · HL
DIVINCI: Dissection of Influenza Vaccination and Infection for Childhood Immunity
$4,907,100Paul Glyndwr Thomas · St. Jude Children'S Research Hospital · U01 · FY2021 · AI
I4C 2.0: Immunotherapy for Cure
$4,904,730Dan H. Barouch · Beth Israel Deaconess Medical Center · UM1 · FY2021 · AI
DIVINCI: Dissection of Influenza Vaccination and Infection for Childhood Immunity
$4,901,799Paul Glyndwr Thomas · St. Jude Children'S Research Hospital · U01 · FY2022 · AI
Duke Clinical Good Manufacturing Practices Facility for HIV/AIDS Vaccine Production
$4,900,000Barton F Haynes · Duke University · C06 · FY2017 · OD
Development and validation of antivirals against Flaviviruses
$4,897,582Sara Cherry · Scripps Research Institute, The · U19 · FY2022 · AI
Immunoprophylactic Strategies to Control Emerging Enteric Infections
$4,894,397Myron Max Levine · University Of Maryland Baltimore · U19 · FY2014 · AI